Business Context and Reporting Period
This Form 8-K Current Report was filed by Clear Channel Outdoor Holdings, Inc. on August 4, 2020. The filing addresses a regulatory notice received from the New York Stock Exchange (NYSE) regarding the Company's compliance with continued listing standards.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only quantitative data provided relates to stock price performance:
- Average Closing Price: Below $1.00 per share over the 30 consecutive trading days preceding August 4, 2020.
- Minimum Requirement: $1.00 per share average closing price to maintain NYSE listing under Section 802.01C.
Material Changes
The primary material event is the receipt of a notice from the NYSE indicating non-compliance with the minimum share price requirement. Consequently, the Company's Common Stock (trading symbol "CCO") will continue to trade on the NYSE but will carry an added designation of ".BC" to indicate non-compliance with listing standards.
Outlook, Management Commentary, and Risks
Management Plan: The Company intends to regain compliance within the six-month cure period. The primary strategy identified is implementing a reverse stock split, subject to approval by the Board of Directors and stockholders at the next annual meeting, unless an accelerated cure is achieved prior to the deadline.
Operational Impact: Management states the notice has no immediate impact on ongoing business operations, SEC reporting requirements, or debt obligations.
Risks: Failure to satisfy the cure period conditions or maintain other listing requirements could lead to delisting from the NYSE. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of regaining compliance.
Investor Verification Checklist
- Verify the current trading status and the ".BC" designation on the NYSE for ticker "CCO".
- Monitor upcoming Board of Directors meetings for proposals regarding a reverse stock split.
- Review the Company's next Annual Meeting of Stockholders for required shareholder approval of the reverse split.
- Track the 30-day average closing price to determine if an accelerated cure is achieved before the six-month deadline.